Press releases
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
- Hansa Biopharma Year-end report January-December 2023
More ▼
Key statistics
On Tuesday, Hansa Biopharma AB (24H:DUS) closed at 2.34, 5.59% above its 52-week low of 2.22, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.37 |
---|---|
High | 2.39 |
Low | 2.34 |
Bid | 2.34 |
Offer | 2.56 |
Previous close | 2.39 |
Average volume | 180.00 |
---|---|
Shares outstanding | 52.67m |
Free float | 48.58m |
P/E (TTM) | -- |
Market cap | 1.52bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 15 minutes, as of Apr 30 2024 18:32 BST.
More ▼